Status:
COMPLETED
Study of the Feasibility to Derive Vaccine From Tumor Tissue in Patients With Non-Small Cell Lung Cancer
Lead Sponsor:
Agenus Inc.
Conditions:
Non-Small-Cell Lung Carcinoma
Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Antigenics is enrolling patients in a Phase II study testing the feasibility to derive an autologous investigational vaccine (HSPPC-96) from the tumor tissue of patients with resectable non-small cell...
Detailed Description
Antigenics is enrolling patients in a Phase II study testing the feasibility to derive an autologous investigational vaccine (HSPPC-96) from the tumor tissue of patients with resectable non-small cell...
Eligibility Criteria
Inclusion
- This is a summary of criteria. Only the Principal Investigator can determine eligibility.
- Suspected non-small cell lung cancer, Stage IB, Stage II, or Stage IIIA
- Tumor size \> 3x3 cm or equivalent to a 9 cm² lesion
- Scheduled surgery with curative intent
- At least 18 years of age
- Must not be pregnant or breast feeding
- Agree to not receive any other investigative agent at any time while enrolled in this study
Exclusion
- Previous treatment for non-small cell lung cancer
- Clinical signs or symptoms of brain metastases
- History of immune suppression or autoimmune disorder
- Severe active infection or other serious medical illness, that in the opinion of the Principal Investigator, would prevent study completion
- Other malignancies in the past 5 years, except adequately treated in situ cervix carcinoma or non-melanoma skin cancer
Key Trial Info
Start Date :
September 1 2003
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00098085
Start Date
September 1 2003
Last Update
March 9 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
London, United Kingdom